Trial Profile
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 May 2023 Results assessing whether docetaxel and trametinib would improve activity in KRAS+ NSCLC and specifically in KRAS G12C NSCLC, published in the Clinical Cancer Research
- 13 Jan 2021 Planned End Date changed from 15 Oct 2020 to 1 Feb 2021.
- 04 Jun 2019 Primary endpoint (Response rate (confirmed and unconfirmed complete and partial responses) in all KRAS mutant patients (both those with G12C mutations and those with non-G12C mutations)) has been met.